Dysport )

Phase 2Small molecule

UUppsala University

Dysport ) is one of 6 small molecule programs targeting Epidermolysis Bullosa Simplex. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Epidermolysis Bullosa SimplexActive, not recruiting

Epidermolysis Bullosa SimplexPhase 2

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Epidermolysis Bullosa Simplex

#DrugCompanyPhaseTrials

E-Mycin

AAzurity Pharmaceuticals

Phase 3

1 2

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Arthodar

AC-203

TTWi Biotechnology, Inc.

Phase 3

—5

Botulinic Toxin

UUniversity Hospital, Toulouse

Phase 3

1 6

Dysport )

UUppsala University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Epidermolysis Bullosa Simplex1 trial

Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita

Unknown status·UUppsala University·Phase 2·NCT00936533·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dysport ). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dysport ) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dysport ). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Uppsala University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUppsala University

Dysport )

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Epidermolysis Bullosa Simplex1 trial

References

Drug Info

Quick Facts

Related News